Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ICN Biomedicals launches cardiovascular risk test:

This article was originally published in Clinica

Executive Summary

ICN Biomedicals, a subsidiary of ISN Pharmaceuticals, has begun selling a high-sensitivity test for the detection of chronic inflammation associated with coronary heart disease. The product measures C-Reactive protein - chronic low levels of this market represent a potential higher risk of cardiovascular disease, ICN says. The Costa Mesa, California company says that nearly half of the 1.3 million people suffering heart attacks annually in the US have no symptoms that could have been detected with conventional cholesterol or lipid marker tests.

Topics

UsernamePublicRestriction

Register

MT074052

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel